(Q44340838)

2 December 2017

Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimer's disease (English)

1 reference

2 December 2017

0 references

0 references

6

Harald Hampel

1 reference

2 December 2017

Peter Schönknecht

1

1 reference

2 December 2017

Johannes Pantel

2

1 reference

2 December 2017

Aoife Hunt

3

1 reference

2 December 2017

Martin Volkmann

4

1 reference

2 December 2017

Katharina Buerger

5

1 reference

2 December 2017

Johannes Schröder

7

1 reference

2 December 2017

language of work or name

English

0 references

publication date

1 March 2003

1 reference

2 December 2017

3

1 reference

inferred from page(s)

published in

Neuroscience Letters

1 reference

2 December 2017

339

1 reference

2 December 2017

172-174

1 reference

2 December 2017

2

1 reference

Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample.

2 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2802%2901481-7

7 January 2021

CSF phosphorylated tau protein and mild cognitive impairment: a prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2802%2901481-7

7 January 2021

CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2802%2901481-7

7 January 2021

CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2802%2901481-7

7 January 2021

Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2802%2901481-7

7 January 2021

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2802%2901481-7

7 January 2021

CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2802%2901481-7

7 January 2021

Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2802%2901481-7

7 January 2021

Cerebrospinal fluid tau levels in Alzheimer's disease are elevated when compared with vascular dementia but do not correlate with measures of cerebral atrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2802%2901481-7

7 January 2021

A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2802%2901481-7

7 January 2021

Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2802%2901481-7

7 January 2021

10.1016/S0304-3940(02)01481-7

Identifiers

DOI

1 reference

2 December 2017

1 reference